A medical device manufacturer just spent $9 million on three AI startups. The market cheered. Five days of gains. Then the volatility hit. Here is the trap.
Context: The Anatomy of a Diversion
Jiuan Medical, the company behind the pandemic-era antigen test boom, now sits on a pile of cash. In 2022, they booked billions in profit. But their core business—home glucometers, blood pressure cuffs—is flatlining. Growth rates have collapsed. So their investment arm did what any cash-rich, growth-starved traditional company does: they bought a ticket to the hype train.
They allocated: - 750 million RMB into DeepSeek (≈$105M) for a 0.21% stake. - $30 million into Kimi (Moonshot AI). - 100 million RMB into LeapStar (Baichuan).
Total: roughly $145 million. For a company that once earned $1B in a quarter, this is discretionary spending. The holding structure is indirect. They have zero operational control, zero board seats, zero technology transfer. This is a portfolio of lottery tickets, not a strategic pivot.
Core: Macro Liquidity Meets the 'Concept' Play
Here is where my background in stress-testing DeFi protocols and auditing Ethereum bridges kicks in. The premise of this article is not about AI. It is about how macro-liquidity cycles drive capital allocation decisions in both traditional markets and crypto. The same forces that push yield farmers into high-risk liquidity pools push corporate treasuries into 'concept' investments.
Based on my experience auditing the DAO aftermath and later stress-testing MakerDAO’s stability fees against 40% ETH drawdowns, I learned one immutable truth: leverage disguised as diversification always fails the stress test.
Jiuan Medical’s investment is exactly that. They are not betting on AI technology—they are betting on the narrative of AI. The tiny stakes (0.21% of DeepSeek) mean they are essentially buying a call option on the hype cycle, much like buying a micro-cap token based on a viral tweet. The correlation to crypto is direct: when the Federal Reserve pivots, risk assets rally. The same liquidity that lifted Bitcoin to $70K greased the wheels for this AI investment.
But here is where the macro watcher sees the fracture. The valuation of DeepSeek implied by this investment is approximately $50 billion. That is a company with negligible revenue, no clear market dominance, and a product that is free via open source. The valuation is based on future expectations that are already priced in for hype. This is exactly what we saw in DeFi Summer 2020—projects valued at billions based on TVL that evaporated in hours.
Failure-mode stress testing is my signature. I run the scenario: what happens when the next rate hike comes? What happens when China tightens its AI regulations? The investment becomes impaired. The market reacts not to the fundamentals of the AI companies, but to the signal that Jiuan Medical is now an 'AI concept stock.' The gains are driven by sentiment, not by synergies. When sentiment shifts, the liquidity that created those gains vanishes—faster than headlines evolve.
Contrarian: This is Not About AI, It's About Capital Desperation
The consensus narrative is that traditional companies are embracing innovation, that this is a vote of confidence in Chinese AI. My contrarian take: this is a symptom of capital desperation. Jiuan Medical has no organic growth engine. They are sitting on cash that is depreciating in real terms. So they buy into the most hyped narrative available—AI. This is no different from a crypto whale buying a governance token for $10M just to be seen as a 'partner.' It is signaling, not strategy.
Chaos is just data that hasn't been stress-tested yet.
The hidden truth is that these investments are theater. The KYC on the counterparty risk is thin. In my 2022 forensic analysis of the Celsius and Three Arrows collapse, I traced how opaque lending flows propagated risk through centralized entities. Here, the risk is similarly opaque: Jiuan Medical has no control over how DeepSeek spends the capital, uses the compute, or manages its cap table. They are a passive passenger in a rocket car with no steering wheel.
Moreover, this investment mirrors the overhyped Data Availability (DA) layer narrative in crypto. 99% of rollups don't generate enough data to need dedicated DA solutions. Similarly, 99% of traditional companies that invest in AI will see zero operational impact. The value is in the story, not the substance.
Takeaway: The Cycle Positioning
We are in a bull market for hype. Crypto, AI, semi-conductors—any narrative that promises exponential returns attracts liquidity. But as a macro watcher, I see this as a warning. When companies like Jiuan Medical—with zero tech expertise in the sector they invest in—start making headline-grabbing bets, it is a sign of late-cycle behavior. The easy money has been made. The next leg requires genuine innovation, not reputation arbitrage.
My forward-looking thought: Watch for the next quarter’s earnings. If Jiuan Medical reports impairment on these investments, the market will learn a lesson about financial theater. In crypto, we call that a 'rug pull.' In traditional markets, they call it a 'strategic retreat.' Either way, the code doesn’t care about your narrative.
Chaos is just data that hasn't been stress-tested yet.
Liquidity vanishes faster than headlines evolve.